Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages

  Muda, Kathrin ^a   Bertinetti, Daniela ^a   Gesellchen, Frank ^b   Hermann, Jennifer Sarah ^a   Von Zweydorf, Felix ^c   Geerlof, Arie ^d   Jacob, Anette ^e   Ueffing, Marius ^c,d   Gloeckner, Christian Johannes ^c,d   Herberg, Friedrich W ^a  

^a UNIVERSITY OF KASSEL   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CAMP dependent protein kinase; Pathogenic mutation; Protein protein interaction

Indexed keywords

ALANINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOPEPTIDE; PROTEIN 14 3 3; PROTEIN 14 3 3 GAMMA; PROTEIN 14 3 3 THETA; PROTEIN 14 3 3 ZETA; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS;

CAMP-DEPENDENT PROTEIN KINASE; PATHOGENIC MUTATION; PROTEIN-PROTEIN INTERACTION;

14-3-3 PROTEINS; ALANINE; ANIMALS; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION; HUMANS; MASS SPECTROMETRY; MUTAGENESIS, SITE-DIRECTED; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

EID: 84891904255     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312701111     Document Type: Article

References (53)

1. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson disease. Annu Rev Neurosci 28: 57-87.
2. Mills RD, Mulhern TD, Cheng HC, Culvenor JG (2012) Analysis of LRRK2 accessory repeat domains: Prediction of repeat length, number and sites of Parkinson's disease mutations. Biochem Soc Trans 40(5): 1086-1089.
3. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: Protein domains and functional insights. Trends Neurosci 29(5): 286-293.
4. Haugarvoll K, Wszolek ZK (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord 15(Suppl 3):S205-S208.
5. Sheng Z, et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4(164): 164ra161.
6. West AB, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102(46): 16842-16847.
7. Gloeckner CJ, et al. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 9(4): 1738-1745.
8. Zach S, Felk S, Gillardon F (2010) Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS One 5(10): e13191.
9. West AB, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16(2): 223-232.
10. Dzamko N, et al. (2012) The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7(6):e39132.
11. Ito G, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46(5): 1380-1388.
12. Li X, et al. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6(3):e17153.
13. Nguyen PV, Woo NH (2003) Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Prog Neurobiol 71(6): 401-437.
14. Choi J, et al. (2002) Phosphorylation of stargazin by protein kinase A regulates its interaction with PSD-95. J Biol Chem 277(14): 12359-12363.
15. Ehlers MD (2000) Reinsertion or degradation of AMPA receptors determined by activity- dependent endocytic sorting. Neuron 28(2): 511-525.
16. Goldsmith BA, Abrams TW (1992) cAMP modulates multiple K+ currents, increasing spike duration and excitability in Aplysia sensory neurons. Proc Natl Acad Sci USA 89(23): 11481-11485.
17. Wolf ME, Mangiavacchi S, Sun X (2003) Mechanisms by which dopamine receptors may influence synaptic plasticity. Ann N Y Acad Sci 1003: 241-249.
18. Lobbestael E, Baekelandt V, Taymans JM (2012) Phosphorylation of LRRK2: From kinase to substrate. Biochem Soc Trans 40(5): 1102-1110.
19. Nichols RJ, et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430(3): 393-404.
20. Bridges D, Moorhead GB (2004) 14-3-3 proteins: A number of functions for a numbered protein. Sci STKE 2004(242):re10.
21. Yaffe MB (2002) How do 14-3-3 proteins work?-Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 513(1): 53-57.
22. Fraser KB, et al. (2013) LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet 22(24): 4988-5000.
23. Foote M, Zhou Y (2012) 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol 3(2): 152-164.
24. Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 22(7): 696-704.
25. Walsh DA, Ashby CD, Gonzalez C, Calkins D, Fischer EH (1971) Krebs EG: Purification and characterization of a protein inhibitor of adenosine 3',5'-monophosphatedependent protein kinases. J Biol Chem 246(7): 1977-1985.
26. Kemp BE, Graves DJ, Benjamini E, Krebs EG (1977) Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. J Biol Chem 252(14): 4888-4894.
27. Hennrich ML, et al. (2013) Universal quantitative kinase assay based on diagonal SCX chromatography and stable isotope dimethyl labeling provides high-definition kinase consensus motifs for PKA and human Mps1. J Proteome Res 12(5): 2214-2224.
28. Shabb JB (2001) Physiological substrates of cAMP-dependent protein kinase. Chem Rev 101(8): 2381-2411.
29. Giles N, Forrest A, Gabrielli B (2003) 14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity. J Biol Chem 278(31): 28580-28587.
30. Yaffe MB, et al. (1997) The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91(7): 961-971.
31. Anand VS, et al. (2009) Investigation of leucine-rich repeat kinase 2: Enzymological properties and novel assays. FEBS J 276(2): 466-478.
32. Jaleel M, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405(2): 307-317.
33. Webber PJ, et al. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 412(1): 94-110.
34. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11(12): 791-797.
35. Seol W (2010) Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep 43(4): 233-244.
36. Dhillon AS, et al. (2002) Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 22(10): 3237-3246.
37. Pungaliya PP, et al. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS ONE 5(10):e13672.
38. Ohta E, Kawakami F, Kubo M, Obata F (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585(14): 2165-2170.
39. Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R (1994) Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 265(5179): 1713-1716.
40. Reuther GW, Pendergast AM (1996) The roles of 14-3-3 proteins in signal transduction. Vitam Horm 52: 149-175.
41. Dougherty MK, Morrison DK (2004) Unlocking the code of 14-3-3. J Cell Sci 117(Pt 10): 1875-1884.
42. Muslin AJ, Tanner JW, Allen PM, Shaw AS (1996) Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84(6): 889-897.
43. Molzan M, Ottmann C (2012) Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3ζ dimer. J Mol Biol 423(4): 486-495.
44. Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H (2011) 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol 22(7): 705-712.
45. Daniëls V, et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116(2): 304-315.
46. Tan Y, Demeter MR, Ruan H, Comb MJ (2000) BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275(33): 25865-25869.
47. Tzivion G, Luo Z, Avruch J (1998) A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394(6688): 88-92.
48. Gasper R, Meyer S, Gotthardt K, Sirajuddin M, Wittinghofer A (2009) It takes two to tango: Regulation of G proteins by dimerization. Nat Rev Mol Cell Biol 10(6): 423-429.
49. Gloeckner CJ, et al. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15(2): 223-232.
50. Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7(23): 4228-4234.
51. Rittinger K, et al. (1999) Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell Biol 4(2): 153-166.
52. Zimmermann B, Chiorini JA, Ma Y, Kotin RM, Herberg FW (1999) PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I. J Biol Chem 274(9): 5370-5378.
53. Thomas J, et al. (1991) Expression in Escherichia coli and characterization of the heatstable inhibitor of the cAMP-dependent protein kinase. J Biol Chem 266(17): 10906-10911.